# OnCo record zoldonrasib (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/zoldonrasib/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "zoldonrasib" ;
  schema:name "Zoldonrasib"@en ;
  schema:description "The first drug aimed specifically at KRAS G12D, the single most common mutation in pancreatic cancer. Early combination data in 2026 showed half of previously treated patients responding."@en ;
  schema:url <https://onco.cc/drugs/zoldonrasib/> ;
  schema:dateModified "2026-09-06"^^xsd:date ;
  schema:citation <https://ir.revmed.com/news-releases/news-release-details/revolution-medicines-presents-phase-12-clinical-data-zoldonrasib>, <https://www.onclive.com/view/zoldonrasib-combinations-show-compelling-antitumor-activity-in-ras-g12d-mutant-metastatic-pdac> ;
  onco:status "phase-2" ;
  onco:modality "Small-molecule RAS(ON) G12D-selective inhibitor" ;
  onco:cancers <https://onco.cc/cancers/pancreatic/>, <https://onco.cc/cancers/metastatic-pdac/>, <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/colorectal/> ;
  onco:technologies <https://onco.cc/technologies/kras-inhibitors/> ;
  onco:targets <https://onco.cc/targets/kras/> ;
  onco:drugs <https://onco.cc/drugs/daraxonrasib/> ;
  onco:companies <https://onco.cc/companies/revolution-medicines/> ;
  onco:pathways <https://onco.cc/pathways/ras-mapk/> ;
  onco:trials <https://onco.cc/trials/nct07805954/>, <https://onco.cc/trials/nct07621718/>, <https://onco.cc/trials/nct07777822/>, <https://onco.cc/trials/nct06445062/>, <https://onco.cc/trials/nct07397338/>, <https://onco.cc/trials/nct06922591/> .